RVPHW
Income statement / Annual
Last year (2023), Reviva Pharmaceuticals Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Reviva Pharmaceuticals Holdings, Inc.'s net income was -$39.26 T.
See Reviva Pharmaceuticals Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
02/29/2020 |
02/28/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$724,740.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
-$724,740.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$31.42 T
|
$18.95 M
|
$4.85 M
|
$295,150.00
|
$195,744.00
|
$946,301.00
|
| General & Administrative
Expenses |
$8.08 T
|
$5.36 M
|
$5.25 M
|
$2.14 M
|
$181,116.00
|
$175,579.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.08 T
|
$5.36 M
|
$5.25 M
|
$2.14 M
|
$181,116.00
|
$175,579.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$0.00 |
| Operating Expenses |
$39.50 T |
$24.31 M |
$10.10 M |
$2.43 M |
$376,860.00 |
$1.12 M |
| Cost And Expenses |
$39.50 M |
$24.31 M |
$10.10 M |
$2.43 M |
$376,860.00 |
$1.12 M |
| Interest Income |
$0.00 |
$182,802.00 |
$0.00 |
$105,183.00 |
$201.00 |
$0.00 |
| Interest Expense |
$0.00 |
$182,802.00 |
$2,414.00 |
$1.45 M |
$469,373.00 |
$0.00 |
| Depreciation &
Amortization |
$0.00
|
$194,709.00
|
$236,558.00
|
$105,774.00
|
$846.00
|
$1,017.00
|
| EBITDA |
-$39.50 T
|
-$24.11 M
|
-$10.10 M
|
-$2.33 M
|
-$376,014.00
|
-$1.12 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$39.50 T
|
-$11,907.00
|
$1.59 M
|
-$1.35 M
|
-$469,172.00
|
-$557,675.00
|
| Income Before Tax |
-$39.24 M |
-$24.32 M |
-$8.52 M |
-$3.78 M |
-$846,032.00 |
-$1.68 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$16.95 B |
$20,777.00 |
$6,004.00 |
$800.00 |
$800.00 |
$800.00 |
| Net Income |
-$39.26 T |
-$24.34 M |
-$8.52 M |
-$3.78 M |
-$846,832.00 |
-$1.68 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.65 |
-1.25 |
-0.58 |
-1.24 |
-0.31 |
0 |
| EPS Diluted |
-1.65 |
-1.25 |
-0.58 |
-1.24 |
-0.31 |
0 |
| Weighted Average Shares
Out |
$23.80 M
|
$19.52 M
|
$14.79 M
|
$3.06 M
|
$2.77 M
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$23.80 M
|
$19.52 M
|
$14.79 M
|
$3.06 M
|
$2.77 M
|
$0.00
|
| Link |
|
|
|
|
|
|
